Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
GNLX | US
-0.28
-9.06%
Healthcare
Biotechnology
30/06/2024
17/10/2024
2.81
3.07
3.08
2.75
Genelux Corporation a clinical-stage biopharmaceutical company focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec a proprietary modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small-cell lung cancer. The company is also developing V2ACT Immunotherapy for the treatment of pancreatic cancer; and V-VET1 an animal health product candidate. It has a licensing agreement with ELIAS Animal Health LLC. Genelux Corporation was incorporated in 2001 and is headquartered in Westlake Village California.
View LessLow Debt to Equity (< 0.25)
Low Debt to Asset (< 0.2)
Value Stock (Price to Book < 3)
High Short-term Volatility
High 6-Month Volatility (>65%)
Microcap (<300M USD)
Weak Operating Margin (< 10%)
Declining Revenue (< 0%)
Weak Sharpe Ratio (< 0.3)
Bearish: Increased Volatility (6-month > 1-month volatility)
10 days
125.1%1 month
105.2%3 months
107.5%6 months
124.5%-
-
2.39
0.06
0.05
-327.19
7.34K
-
-26.96M
97.04M
97.04M
-
-341.44K
-
-95.30
-88.57
5.72
3.84
Short-term: Bullish (SMA10D > SMA1M)
Intermediate-term: Bullish (SMA1M > SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
Range10D
1.20
Range1M
1.65
Range3M
2.00
Rel. volume
0.66
Price X volume
285.73K
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
Genenta Science S.p.A | GNTA | Biotechnology | 5.76 | 104.93M | -1.54% | n/a | 0.00% |
Prelude Therapeutics Incorporated | PRLD | Biotechnology | 1.92 | 104.84M | -1.03% | n/a | 9.99% |
CIBUS GLOBAL LTD. | CBUS | Biotechnology | 3.46 | 102.04M | -6.49% | n/a | 81.33% |
AVTX | AVTX | Biotechnology | 10.4 | 100.88M | 1.07% | n/a | -80.47% |
Regulus Therapeutics Inc | RGLS | Biotechnology | 1.52 | 99.51M | -4.40% | n/a | 1.45% |
INmune Bio Inc | INMB | Biotechnology | 5 | 99.16M | -4.03% | n/a | 14.65% |
Agenus Inc | AGEN | Biotechnology | 4.57 | 98.58M | -2.35% | n/a | -170.56% |
Oncolytics Biotech Inc. (USA) | ONCY | Biotechnology | 1.28 | 98.38M | 2.40% | n/a | 0.00% |
Oramed Pharmaceuticals Inc | ORMP | Biotechnology | 2.4 | 97.85M | -1.23% | 4.67 | 0.00% |
Coherus BioSciences Inc | CHRS | Biotechnology | 0.8482 | 97.72M | -4.33% | n/a | -354.71% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
Kewaunee Scientific Corporation | KEQU | Building Products & Equipment | 32.05 | 92.04M | -1.35% | 5.27 | 19.82% |
Saga Communications Inc | SGA | Broadcasting - Radio | 14.35 | 89.85M | 0.07% | 14.47 | 7.10% |
Beasley Broadcast Group Inc | BBGI | Broadcasting - Radio | 12.6 | 19.19M | 0.80% | n/a | 204.46% |
ILAG | ILAG | Building Products & Equipment | 0.98 | 17.70M | -3.92% | n/a | 5.48% |
Antelope Enterprise Holdings Limited | AEHL | Building Products & Equipment | 0.5763 | 8.36M | -11.91% | 0.04 | 16.03% |
Forza X1 Inc | FRZA | Recreational Vehicles | 0.2111 | 3.79M | 2.93% | n/a | 0.97% |
EZGO Technologies Ltd. Ordinary Shares | EZGO | Recreational Vehicles | 1.04 | 2.71M | -4.59% | n/a | 9.62% |
Micromobility.com Inc. | MCOM | Recreational Vehicles | 0.0114 | 1.02M | 14.00% | n/a | -37.05% |
Winnebago Industries Inc | WGO | Recreational Vehicles | 60.16 | 0 | -0.43% | n/a | |
Vision Marine Technologies Inc | VMAR | Recreational Vehicles | 4.3 | 0 | 2.14% | n/a |
Parameter | Company | Industry | Indicator |
---|---|---|---|
Enterprise to EBITDA | -327.19 | 0.53 | Cheaper |
Ent. to Revenue | 7,338.57 | 4,005.99 | Expensive |
PE Ratio | - | 40.42 | - |
Price to Book | 2.39 | 15.30 | Cheaper |
Dividend Yield | - | 2.20 | - |
Std. Deviation (3M) | 107.52 | 72.92 | Riskier |
Debt to Equity | 0.06 | -1.24 | Expensive |
Debt to Assets | 0.05 | 0.25 | Cheaper |
Market Cap | 97.04M | 3.78B | Emerging |